MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.23
-0.91
-2.21%
Closed 16:00 11/27 EST
OPEN
41.16
PREV CLOSE
41.14
HIGH
41.40
LOW
39.55
VOLUME
786.57K
TURNOVER
--
52 WEEK HIGH
41.55
52 WEEK LOW
12.71
MARKET CAP
5.44B
P/E (TTM)
262.26
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now?
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 1d ago
Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer
Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Zacks · 3d ago
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
Zacks · 4d ago
A Look Into Halozyme Therapeutics's Debt
Benzinga · 5d ago
Halozyme raises FY20 guidance on Horizon Therapeutics global collaboration
Halozyme Therapeutics (HALO) updated FY20 financial guidance reflecting the signing of a global collaboration and license agreement with Horizon Therapeutics.FY20 revenue guidance raised to $265M to $275M (vs. $250 to $260M
Seekingalpha · 5d ago
Halozyme Raises FY20 GAAP EPS Guidance From $0.80-$0.85 To $0.90-$0.95 vs $0.86 Est., Raises Sales Guidance From $250M-$260M To $265M-$275M vs $255.12M
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and
Benzinga · 5d ago
Halozyme Therapeutics Raises FY2020 Sales Guidance from $250.00M-260.00M to $265.00M-275.00M
Halozyme Therapeutics (NASDAQ:HALO) raises FY2020 sales outlook from $250.00 million-260.00 million to $265.00 million-275.00 million.
Benzinga · 5d ago
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressive and vision-threatening rare autoimmune disease,1 potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.
PR Newswire · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HALO. Analyze the recent business situations of Halozyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HALO stock price target is 39.36 with a high estimate of 60.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 395
Institutional Holdings: 149.04M
% Owned: 110.25%
Shares Outstanding: 135.18M
TypeInstitutionsShares
Increased
88
8.14M
New
59
371.87K
Decreased
97
9.78M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Elaine Sun
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Kenneth Kelley
Independent Director
Matthew Posard
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HALO
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.